A detailed history of Black Rock Inc. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 10,332,078 shares of XERS stock, worth $34.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,332,078
Previous 9,960,506 3.73%
Holding current value
$34.9 Million
Previous $22 Million 5.61%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.7 - $2.45 $631,672 - $910,351
371,572 Added 3.73%
10,332,078 $23.2 Million
Q1 2024

May 10, 2024

SELL
$2.04 - $3.22 $103,805 - $163,849
-50,885 Reduced 0.51%
9,960,506 $22 Million
Q4 2023

Feb 13, 2024

BUY
$1.47 - $2.36 $936,609 - $1.5 Million
637,149 Added 6.8%
10,011,391 $23.5 Million
Q3 2023

Nov 13, 2023

BUY
$1.8 - $2.69 $71,362 - $106,647
39,646 Added 0.42%
9,374,242 $17.4 Million
Q2 2023

Aug 11, 2023

BUY
$1.82 - $2.98 $1.68 Million - $2.75 Million
921,416 Added 10.95%
9,334,596 $24.5 Million
Q1 2023

May 12, 2023

SELL
$1.03 - $1.63 $167,923 - $265,743
-163,033 Reduced 1.9%
8,413,180 $13.7 Million
Q4 2022

Feb 13, 2023

BUY
$1.14 - $1.65 $396,246 - $573,515
347,585 Added 4.22%
8,576,213 $11.4 Million
Q3 2022

Nov 14, 2022

BUY
$1.37 - $1.93 $303,912 - $428,139
221,834 Added 2.77%
8,228,628 $12.8 Million
Q2 2022

Aug 12, 2022

BUY
$1.48 - $2.64 $8.9 Million - $15.9 Million
6,011,915 Added 301.37%
8,006,794 $12.3 Million
Q1 2022

May 12, 2022

BUY
$2.0 - $2.87 $398,732 - $572,180
199,366 Added 11.1%
1,994,879 $5.11 Million
Q4 2021

Feb 10, 2022

BUY
$1.8 - $2.93 $3.23 Million - $5.26 Million
1,795,513 New
1,795,513 $5.26 Million

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $460M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.